BridgeBio Oncology Therapeutics, Inc. (BBOT)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGM
8.52 USD
+0.20
(2.404%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 8.52 |
Hot Take ↕ | July 11, 2026, 4:50 a.m. EDT
The immediate outlook is mixed due to conflicting signals. While the stock recently rallied off its lows, the short-term statistical forecast predicts a modest decline over the next 45 days, suggesting the recent bounce may be running out of steam. However, the fundamental picture is starkly different: the company is a pre-revenue biotech with negative earnings, negative free cash flow, and no history of paying dividends. Consequently, there is no income component to offset the high volatility typical of this sector. The long-term potential hinges entirely on the success of their KRAS G12C therapy pipeline, which analysts view as a significant opportunity, but the current financial reality—characterized by burning cash and no profitability—means this remains a speculative bet rather than a solid investment. Until the pipeline delivers commercial results or the balance sheet stabilizes, the risk profile remains elevated. |
| Model | MAE |
|---|---|
| MSTL_67_101 ✓ | 0.088478 |
| AutoARIMA | 0.088529 |
| MSTL_101 | 0.098532 |
| MSTL_67 | 0.099590 |
| AutoETS | 0.102318 |
| AutoTheta | 0.104903 |
| MSTL | 0.110107 |
Forecast horizon: 60 days | Selected: MSTL_67_101
| Forecast Reliability | |
|---|---|
| Score | 49% |
| H-stat | 1.59 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.342 |
| Excess Kurtosis | -0.93 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.71 |
| Market Cap | 682,512,576 |
| Forward P/E | -4.04 |
| Beta | 0.39 |
| Website | https://bbotx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.22024369 |
| Address1 | 256 East Grand Avenue |
| Address2 | Suite 104 |
| All Time High | 14.87 |
| All Time Low | 7.0 |
| Ask | 10.4 |
| Ask Size | 2 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 453,530 |
| Average Daily Volume3 Month | 464,770 |
| Average Volume | 464,770 |
| Average Volume10Days | 453,530 |
| Beta | 0.388 |
| Bid | 6.12 |
| Bid Size | 2 |
| Book Value | 4.648 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.52 |
| Current Ratio | 6.16 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 8.58 |
| Day Low | 8.045 |
| Debt To Equity | 0.71 |
| Display Name | BridgeBio Oncology Therapeutics |
| Earnings Call Timestamp End | 1,773,421,200 |
| Earnings Call Timestamp Start | 1,773,421,200 |
| Earnings Timestamp End | 1,786,478,400 |
| Earnings Timestamp Start | 1,786,478,400 |
| Ebitda | -168,560,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.568 |
| Enterprise Value | 432,881,536 |
| Eps Current Year | -2.21262 |
| Eps Forward | -2.10647 |
| Eps Trailing Twelve Months | -1.97 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.1278 |
| Fifty Day Average Change | 0.39220047 |
| Fifty Day Average Change Percent | 0.0482542 |
| Fifty Two Week Change Percent | -22.024368 |
| Fifty Two Week High | 14.87 |
| Fifty Two Week High Change | -6.3499994 |
| Fifty Two Week High Change Percent | -0.42703426 |
| Fifty Two Week Low | 7.0 |
| Fifty Two Week Low Change | 1.5200005 |
| Fifty Two Week Low Change Percent | 0.21714292 |
| Fifty Two Week Range | 7.0 - 14.87 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,707,489,000,000 |
| Float Shares | 35,669,290 |
| Forward Eps | -2.10647 |
| Forward P E | -4.0446815 |
| Free Cashflow | -86,092,128 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 106 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.27114 |
| Held Percent Institutions | 0.68902 |
| Implied Shares Outstanding | 80,107,104 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California. |
| Long Name | BridgeBio Oncology Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 682,512,576 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_623256762 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -154,095,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 666,491,105 |
| Number Of Analyst Opinions | 10 |
| Open | 8.29 |
| Operating Cashflow | -130,212,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 650 405 4770 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 8.52 |
| Post Market Time | 1,783,975,628 |
| Previous Close | 8.32 |
| Price Eps Current Year | -3.8506389 |
| Price Hint | 2 |
| Price To Book | 1.8330467 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.835 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.36364 |
| Region | US |
| Regular Market Change | 0.200001 |
| Regular Market Change Percent | 2.40386 |
| Regular Market Day High | 8.58 |
| Regular Market Day Low | 8.045 |
| Regular Market Day Range | 8.045 - 8.58 |
| Regular Market Open | 8.29 |
| Regular Market Previous Close | 8.32 |
| Regular Market Price | 8.52 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 482,039 |
| Return On Assets | -0.37195 |
| Return On Equity | -0.62208 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 80,107,104 |
| Shares Percent Shares Out | 0.0651 |
| Shares Short | 5,212,731 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,866,368 |
| Short Name | BridgeBio Oncology Therapeutics |
| Short Percent Of Float | 0.183 |
| Short Ratio | 10.81 |
| Source Interval | 15 |
| State | CA |
| Symbol | BBOT |
| Target High Price | 41.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 25.3 |
| Target Median Price | 23.5 |
| Total Cash | 252,275,008 |
| Total Cash Per Share | 3.149 |
| Total Debt | 2,644,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.97 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.380875 |
| Two Hundred Day Average Change | -1.8608742 |
| Two Hundred Day Average Change Percent | -0.17925987 |
| Type Disp | Equity |
| Volume | 482,039 |
| Website | https://bbotx.com |
| Zip | 94,080 |